Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells

被引:86
作者
Mego, Michal [2 ,3 ,4 ]
De Giorgi, Ugo [2 ,3 ]
Dawood, Shahenaah [3 ]
Wang, Xuemei [5 ]
Valero, Vicente [3 ]
Andreopoulou, Eleni [3 ]
Handy, Beverly [3 ]
Ueno, Naoto T. [3 ]
Reuben, James M. [2 ]
Cristofanilli, Massimo [1 ]
机构
[1] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[2] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Dept Hematopathol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Comenius Univ, Sch Med, Dept Med Oncol, Bratislava, Slovakia
[5] Comenius Univ, Sch Med, Dept Biostat, Bratislava, Slovakia
关键词
circulating tumor cells; prognostic factor; breast cancer; EPITHELIAL-MESENCHYMAL TRANSITION; PROGNOSTIC FACTORS; PERIPHERAL-BLOOD; CHEMOTHERAPY; SURVIVAL; SYSTEM;
D O I
10.1002/ijc.25690
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Circulating tumor cells (CTC) are an independent prognostic factor in metastatic breast cancer patients (MBC). However, CTC are undetectable in one third of patients. The aim of this study was to assess the prognostic factors in MBC patients without detectable CTC. This retrospective study included 292 MBC patients evaluated between January 2004 and December 2007. CTC were enumerated before patients started a new line of treatment using the CellSearch (TM). Overall survival (OS) was calculated from the date of CTC measurement and estimated by the Kaplan-Meier product limit method. CTC were not detected in 35.96% patients, whereas 40.75% patients had CTC >= 5. Undetectable CTC status was positively correlated with presence of brain metastasis (OR: 6.17, 95% CI 5 2.14-17.79; p = 0.001), and inversely correlated with bone metastasis (OR: 0.47; 95% CI = 0.27-0.80; p = 0.01). In multivariate analysis, hormone receptors, number of metastatic sites and lines of therapy were independent prognostic factors for OS in patients without detectable CTC. Patients without detectable CTC before starting of a new line of therapy comprise a heterogeneous group with substantially different prognosis. We showed that some important metastatic disease characteristics are predictive of undetectable CTC status in MBC.
引用
收藏
页码:417 / 423
页数:7
相关论文
共 21 条
  • [1] Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
    Allard, WJ
    Matera, J
    Miller, MC
    Repollet, M
    Connelly, MC
    Rao, C
    Tibbe, AGJ
    Uhr, JW
    Terstappen, LWMM
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (20) : 6897 - 6904
  • [2] BRAIN METASTASES IN BREAST-CANCER - NATURAL-HISTORY, PROGNOSTIC FACTORS AND OUTCOME
    BOOGERD, W
    VOS, VW
    HART, AAM
    BARIS, G
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1993, 15 (02) : 165 - 174
  • [3] Circulating tumor cells versus imaging - Predicting overall survival in metastatic breast cancer
    Budd, G. Thomas
    Cristofanilli, Massimo
    Ellis, Mathew J.
    Stopeck, Allison
    Borden, Ernest
    Miller, M. Craig
    Matera, Jeri
    Repollet, Madeline
    Doyle, Gerald V.
    Terstappen, Leon W. M. M.
    Hayes, Daniel F.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (21) : 6403 - 6409
  • [4] Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?
    Cardoso, F
    Di Leo, A
    Lohrisch, C
    Bernard, C
    Ferreira, F
    Piccart, MJ
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (02) : 197 - 207
  • [5] Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Cristofanilli, M
    Budd, GT
    Ellis, MJ
    Stopeck, A
    Matera, J
    Miller, MC
    Reuben, JM
    Doyle, GV
    Allard, WJ
    Terstappen, LWMM
    Hayes, DF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) : 781 - 791
  • [6] Circulating tumor cells in metastatic breast cancer: Biologic staging beyond tumor burden
    Cristofanilli, Massimo
    Broglio, Kristine R.
    Guarneri, Valentina
    Jackson, Summer
    Fritsehe, Herbert A.
    Islam, Rabinl
    Dawood, Shaheenah
    Reuben, James M.
    Kau, Shu-Wan
    Lara, Juanita M.
    Krishnamurthy, Savitri
    Ueno, Naoto T.
    Hortobagyi, Gabriel N.
    Valero, Vicente
    [J]. CLINICAL BREAST CANCER, 2007, 7 (06) : 471 - 479
  • [7] Circulating Tumor Cells in Metastatic Breast Cancer From Prognostic Stratification to Modification of the Staging System?
    Dawood, Shaheenah
    Broglio, Kristine
    Valero, Vicente
    Reuben, James
    Handy, Beverly
    Islam, Rabiul
    Jackson, Summer
    Hortobagyi, Gabriel N.
    Fritsche, Herbert
    Cristofanilli, Massimo
    [J]. CANCER, 2008, 113 (09) : 2422 - 2430
  • [8] Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer
    De Giorgi, U.
    Valero, V.
    Rohren, E.
    Mego, M.
    Doyle, G. V.
    Miller, M. C.
    Ueno, N. T.
    Handy, B. C.
    Reuben, J. M.
    Macapinlac, H. A.
    Hortobagyi, G. N.
    Cristofanilli, M.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (01) : 33 - 39
  • [9] Circulating Tumor Cells and [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer
    De Giorgi, Ugo
    Valero, Vicente
    Rohren, Eric
    Dawood, Shaheenah
    Ueno, Naoto T.
    Miller, M. Craig
    Doyle, Gerald V.
    Jackson, Summer
    Andreopoulou, Eleni
    Handy, Beverly C.
    Reuben, James M.
    Fritsche, Herbert A.
    Macapinlac, Homer A.
    Hortobagyi, Gabriel N.
    Cristofanilli, Massimo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3303 - 3311
  • [10] Micrometastatic spread in breast cancer:: detection, molecular characterization and clinical relevance
    Fehm, Tanja
    Mueller, Volkmar
    Alix-Panabieres, Catherine
    Pantel, Klaus
    [J]. BREAST CANCER RESEARCH, 2008, 10 (Suppl 1)